TARBP2 and hepatocellular carcinoma: Our results demonstrated that suppression of TARBP2 expression promoted sorafenib resistance in HCC cells (Fig. 2E–H), and downregulation of TARBP2 was correlated with poor outcomes in patients with HCC (Fig. 1A–D), suggesting that miRNA biogenesis factors are globally repressed in HCC cancer progression.